Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
The newly granted patent enriches Salipro Biotech's comprehensive intellectual property (IP) portfolio, securing its method for stabilizing challenging dru...
Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete ...
Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider o...
Debiopharm a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectiou...
AstraZeneca intends to invest £450 million to research, develop and manufacture vaccines in Speke, Liverpool, a facility which will be operationall...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, ...
Clinical Microbiomics A/S^1, the global microbiome science company, announces the acquisition of DNASense ApS, an innovative Danish microbiome C...
BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
For over three decades, LOGIQ has been at the forefront of ultrasound imaging, providing clinicians with reliable, high-quality solutions. The latest...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
© 2024 Biopharma Boardroom. All Rights Reserved.
